Novartis

[unable to retrieve full-text content]

New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients

  Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC

CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment

Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part

  Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines

DisclaimerThese materials contain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking

Starting May 11, 2020, Novartis will introduce company-wide a flexible working model that invites associates, country-by-country, to return to the

Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for

If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in

New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression

[unable to retrieve full-text content]

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical

Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and

Real-world evidence supports benefits seen in Aimovig clinical trials   Open-label data highlight long-term efficacy and safety profile of Aimovig

Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported,

Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial drug hydroxychloroquine to

New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm   Cytokine storm is a type

Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C)

Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with

EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on

Collaboration to address product development and scale up challenges posed by current pandemic  Basel, March 26, 2020 — Today, Novartis

SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint

Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones